View Item 

Show simple item record

Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma‐derived factor concentrates in the era of nucleic acid test screening
dc.contributor.authorSoucie, J. Michaelen_US
dc.contributor.authorDe Staercke, Christineen_US
dc.contributor.authorMonahan, Paul E.en_US
dc.contributor.authorRecht, Michaelen_US
dc.contributor.authorChitlur, Meera B.en_US
dc.contributor.authorGruppo, Ralphen_US
dc.contributor.authorHooper, W. Craigen_US
dc.contributor.authorKessler, Craigen_US
dc.contributor.authorKulkarni, Roshnien_US
dc.contributor.authorManco‐johnson, Marilyn J.en_US
dc.contributor.authorPowell, Jerryen_US
dc.contributor.authorPyle, Meredithen_US
dc.contributor.authorRiske, Brendaen_US
dc.contributor.authorSabio, Hernanen_US
dc.contributor.authorTrimble, Seanen_US
dc.date.accessioned2013-06-18T18:32:30Z
dc.date.available2014-08-01T19:11:32Zen_US
dc.date.issued2013-06en_US
dc.identifier.citationSoucie, J. Michael; De Staercke, Christine; Monahan, Paul E.; Recht, Michael; Chitlur, Meera B.; Gruppo, Ralph; Hooper, W. Craig; Kessler, Craig; Kulkarni, Roshni; Manco‐johnson, Marilyn J. ; Powell, Jerry; Pyle, Meredith; Riske, Brenda; Sabio, Hernan; Trimble, Sean (2013). "Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasmaâ derived factor concentrates in the era of nucleic acid test screening." Transfusion (6): 1217-1225. <http://hdl.handle.net/2027.42/98209>en_US
dc.identifier.issn0041-1132en_US
dc.identifier.issn1537-2995en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/98209
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherBlackwell Publishing Incen_US
dc.titleEvidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma‐derived factor concentrates in the era of nucleic acid test screeningen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationotherFrom the Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia; the University of North Carolina, Chapel Hill, North Carolina; the Oregon Health and Science University, Portland, Oregon; the Children's Hospital of Michigan, Detroit, Michigan; the Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; the Lombardi Cancer Center, Washington, DC; Michigan State University, East Lansing, Michigan; the University of Colorado School of Medicine, Aurora, Colorado; the University of California‐Davis, Sacramento, California; and Wake Forest University, Winston‐Salem, North Carolina.en_US
dc.identifier.pmid22998193en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/98209/1/trf3907.pdf
dc.identifier.doi10.1111/j.1537-2995.2012.03907.xen_US
dc.identifier.sourceTransfusionen_US
dc.identifier.citedreferenceWu C, Mason B, Jong J, Erdman D, McKernan L, Oakley M, Soucie M, Evatt B, Yu MW. Parvovirus B19 transmission by a high‐purity factor VIII concentrate. Transfusion 2005; 45: 1003 ‐ 10.en_US
dc.identifier.citedreferenceCenters for Disease Control and Prevention. Risks associated with human parvovirus B19 infection. MMWR Morb Mortal Wkly Rep 1989; 38: 81 ‐ 8, 93 ‐ 7.en_US
dc.identifier.citedreferencede Jong EP, Walther FJ, Kroes AC, Oepkes D. Parvovirus B19 infection in pregnancy: new insights and management. Prenat Diagn 2011; 31: 419 ‐ 25.en_US
dc.identifier.citedreferenceLamont RF, Sobel JD, Vaisbuch E, Kusanovic JP, Mazaki‐Tovi S, Kim SK, Uldbjerg N, Romero R. Parvovirus B19 infection in human pregnancy. BJOG 2010; 118: 175 ‐ 86.en_US
dc.identifier.citedreferenceColmegna I, Alberts‐Grill N. Parvovirus B19: its role in chronic arthritis. Rheum Dis Clin North Am 2009; 35: 95 ‐ 110.en_US
dc.identifier.citedreferenceTzang BS, Tsai CC, Tsay GJ, Wang M, Sun YS, Hsu TC. Anti‐human parvovirus B19 nonstructural protein antibodies in patients with rheumatoid arthritis. Clin Chim Acta 2009; 405: 76 ‐ 82.en_US
dc.identifier.citedreferenceNocton JJ, Miller LC, Tucker LB, Schaller JG. Human parvovirus B19‐associated arthritis in children. J Pediatr 1993; 122: 186 ‐ 90.en_US
dc.identifier.citedreferenceMurai C, Munakata Y, Takahashi Y, Ishii T, Shibata S, Muryoi T, Funato T, Nakamura M, Sugamura K, Sasaki T. Rheumatoid arthritis after human parvovirus B19 infection [letter]. Ann Rheum Dis 1999; 58: 130 ‐ 32.en_US
dc.identifier.citedreferenceAltschuler EL. Parvovirus B19 and the pathogenesis of rheumatoid arthritis: a case for historical reasoning. Lancet 1999; 354: 1026 ‐ 7.en_US
dc.identifier.citedreferenceTakahashi Y, Murai C, Shibata S, Munakata Y, Ishii T, Ishii K, Saitoh T, Sawai T, Sugamura K, Sasaki T. Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci U S A 1998; 95: 8227 ‐ 32.en_US
dc.identifier.citedreferenceKishore J, Misra R, Gupta D, Ayyagari A. Raised IgM antibodies to parvovirus B19 in juvenile rheumatoid arthritis. Indian J Med Res 1998; 107: 15 ‐ 8.en_US
dc.identifier.citedreferenceKleinman SH, Glynn SA, Lee TH, Tobler L, Montalvo L, Todd D, Kiss JE, Shyamala V, Busch MP; National Heart, Lung, Blood Institute Retrovirus Epidemiology Donor Study (REDS‐II). Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay. Transfusion 2007; 47: 1756 ‐ 64.en_US
dc.identifier.citedreferenceSchmidt I, Blumel J, Seitz H, Willkommen H, Lower J. Parvovirus in plasma pools and plasma derivatives. Vox Sang 2001; 81: 228 ‐ 35.en_US
dc.identifier.citedreferenceAzzi A, Morfini M, Mannucci PM. The transfusion‐associated transmission of parvovirus B19. Transfus Med Rev 1999; 13: 194 ‐ 204.en_US
dc.identifier.citedreferenceSantagostino E, Mannucci PM, Gringeri A, Azzi A, Morfini M, Musso R, Santoro R, Schiavoni M. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100°C heat after lyophilization. Transfusion 1997; 37: 517 ‐ 22.en_US
dc.identifier.citedreferenceSoucie JM, Siwak EB, Hooper WC, Evatt BL, Hollinger FB; the Universal Data Collection Project Working Group. Human parvovirus B19 in young males with hemophilia A: associations with treatment product exposure and joint range‐of‐motion limitation. Transfusion 2004; 44: 1179 ‐ 85.en_US
dc.identifier.citedreferenceZakrzewska K, Azzi A, De Biasi E, Radossi P, De Santis R, Davoli PG, Tagariello G. Persistence of parvovirus B19 DNA in synovium of patients with haemophilic arthritis. J Med Virol 2001; 65: 402 ‐ 7.en_US
dc.identifier.citedreferenceAllain JP, Thomas I, Sauleda S. Nucleic acid testing for emerging viral infections. Transfus Med 2002; 12: 275 ‐ 83.en_US
dc.identifier.citedreferenceGeng Y, Wu C, Bhattacharyya SP, Tan D, Guo Z, Yu MW. Parvovirus B19 in factor VIII concentrates; effects of manufacturing procedures and B19 screening by nucleic acid testing. Transfusion 2007; 47: 883 ‐ 9.en_US
dc.identifier.citedreferenceSoucie JM, McAlister S, McClellan A, Oakley M, Su Y. The universal data collection surveillance system for rare bleeding disorders. Am J Prev Med 2010; 38 Suppl: S475 ‐ 81.en_US
dc.identifier.citedreferenceSoucie JM, Wang C, Forsyth A, Funk S, Denney M, Roach KE, Boone D; the Hemophilia Treatment Center Network. Range of motion measurements: reference values and a database for comparison studies. Haemophilia 2011; 17: 500 ‐ 7.en_US
dc.identifier.citedreferenceNewcombe RG. Two‐sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998; 17: 857 ‐ 72.en_US
dc.identifier.citedreferenceLeFrere JJ, Servant‐Delmas A, Candotti D, Mariotti M, Thomas I, Brossard Y, Lefrère F, Girot R, Allain JP, Laperche S. Persistent B19 infection in immune competent individuals: implications for transfusion safety. Blood 2005; 106: 2890 ‐ 5.en_US
dc.identifier.citedreferenceDoyle S, Corcoran A. The immune response to parvovirus B19 exposure in previously seronegative and seropositive individuals. J Infect Dis 2006; 194: 154 ‐ 8.en_US
dc.identifier.citedreferenceYoung NS, Brown KE. Parvovirus B19. N Engl J Med 2004; 350: 586 ‐ 97.en_US
dc.identifier.citedreferenceCassinotti P, Siegl G, Michel BA, Bruhlmann P. Presence and significance of human parvovirus B19 DNA in synovial membranes and bone marrow from patients with arthritis of unknown origin. J Med Virol 1998; 56: 199 ‐ 204.en_US
dc.identifier.citedreferenceLu J, Zhi N, Wong S, Brown KE. Activation of synoviocytes by the secreted phospholipase A2 motif in the VP1‐unique region of parvovirus B19 minor capsid protein. J Infect Dis 2006; 193: 582 ‐ 90.en_US
dc.identifier.citedreferenceRay NB, Nieva DR, Seftor EA, Khalkhali‐Ellis Z, Naides SJ. Induction of an invasive phenotype by human parvovirus B19 in normal human synovial fibroblasts. Arthritis Rheum 2001; 44: 1582 ‐ 6.en_US
dc.identifier.citedreferenceSharp CP, Lail A, Donfield S, Gomperts ED, Simmonds P. Virologic and clinical features of primary infection with human parvovirus 4 in subjects with hemophilia: frequent transmission by virally inactivated clotting factor concentrates. Transfusion 2012; 52: 1482 ‐ 9.en_US
dc.identifier.citedreferenceSoucie JM, Richardson LC, Evatt B, Linden J, Ewenstein BM, Stein S, Leissinger C, Manco‐Johnson M, Sexauer C; the Hemophilia Surveillance System Project Investigators. Risk factors for infection with hepatitis B and hepatitis C viruses in a large cohort of hemophilic males. Transfusion 2001; 41: 338 ‐ 43.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
trf3907.pdf
Size:
182.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.